Published:17/06/2020

Andreas Meliniotis, Director of Device Development at Vectura, discusses the key considerations to reduce risk when developing a DPI product from early clinical trials through to scale-up, and provides insights for both novel and generic development programs.

Register here: https://bit.ly/30qtaz4

Attachments

  • Original document
  • Permalink

Disclaimer

Vectura Group plc published this content on 17 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 June 2020 12:31:09 UTC